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Abstract: Pigmented villonodular synovitis (PVNS) of the ankle is a very rare, locally aggressive,
proliferative disorder. Although surgical excision represents the standard curative treatment,
the PVNS relapse rate is high. We present our study of five young athletes (range 20–36 years)
with a histopathological diagnosis of PVNS of the ankle, who were treated by surgery and adjuvant
radiosynoviorthesis (RSO). The operation involved either arthroscopic (four patients) or open (one
patient) debridement, followed by intraarticular RSO with the radiopharmaceutical erbium-169
(169Er). They were evaluated with the Foot Function Index (FFI) and a visual analog scale (VAS) for
pain. At a median follow up period of 47 months (range 36–54 months), all five patients reported
marked pain relief with improvements in their daily activities. In particular, the median FFI decreased
from 77% (range 71.0%–84.5%) pre-treatment, to 0.5% (range 0%–6%) after treatment. The median
VAS score decreased from 4 (range 3–7) to 0 (range 0–1), respectively. Throughout the follow-up
period, there were no major complications regarding either therapeutic intervention (arthroscopic or
open debridement, RSO). Based on these results, it can be concluded that adjuvant RSO with 169Er
following surgical excision is effective and safe in the treatment of PVNS of the ankle.
Keywords: ankle pigmented villonodular synovitis (PVNS); radiosynoviorthesis (RSO); erbium-169 (169Er)
1. Introduction
Pigmented villonodular synovitis (PVNS) is a rare, idiopathic, locally aggressive, proliferative
disorder of unknown etiology that may focally or diffusely involve the synovial tissue of the joint [1].
Most cases are monoarticular. The knee is the most commonly affected site, although the phalangeal
joints, hip, ankle, and shoulder can also be involved [2]. The ankle joint is rarely affected by the disease,
with an estimated incidence of 2.5% of all PVNS cases [3].
Surgical excision represents the standard curative treatment for both localized and diffuse PVNS of
the foot and ankle [4,5]. However, due to the complex anatomy of the area which allows the spreading
of the disease to adjacent articular spaces, the complete excision of the highly proliferative synovium is
difficult to achieve, resulting in a significant risk of inadequate excision and recurrence [6–8]. In this
context, adjuvant radiotherapy has been suggested in cases where the complete resection of the lesions
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cannot be accomplished. Despite the rather satisfying reported results, the documented long-term
benefits of this strategy in the particular joint are still limited [6,9–11].
Radiosynoviorthesis (RSO) is another adjuvant therapy that has only rarely been applied in
the treatment of ankle joint PVNS, with conflicting results [12,13]. However, in the published
studies, the authors used the high-energy β-emitting radiopharmaceutical Yttrium-90 (90Y), which is
characterized by a tissue penetration of 3 to 11 mm. Currently, this agent is indicated primarily for
knee joints and not for joints with a narrow joint space and a thin soft tissue envelope, such as the
ankle [14].
In this case series, we present our study of five young athletes suffering from PVNS of the
ankle joint who were treated with synovectomy followed by adjuvant intraarticular RSO with the
radiopharmaceutical erbium-169 (169Er).
2. Materials and Methods
2.1. Patients
Five young amateur athletes suffering from diffuse PVNS of the ankle joint underwent arthroscopic
(four patients) or open (one patient) synovectomy between 01/2015 and 01/2017. There were three
female and two male patients, aged from 20 to 36 years (mean age: 28.2 years). All the patients
had at least one preoperative contrast-enhanced MRI. In all cases, the diagnosis was confirmed by
histopathology. The present study was performed in accordance with the ethical standards laid down
in the 1964 Declaration of Helsinki and all subsequent revisions. All persons gave their informed
consent prior to their inclusion in the study.
2.2. Synovectomy
An arthroscopic debridement of the synovium was performed under tourniquet with the use of
an anterior or posterior ankle arthroscopy or a combination of the above (Figure 1).
J. lin. ed. 2020, 9, x FOR PEER REVIEW 2 of 8 
 
of the lesions cannot be accomplished. Despite the rather satisfying reported results, the documented 
long-term benefits of this strategy in the particular joint are still limited [6,9–11]. 
Radiosynoviorthesis (RSO) is another adjuvant therapy that has only rarely been applied in the 
treatment of ankle joint PVNS, with conflicting results [12,13]. However, in the published studies, the 
authors used the high-energy β-emitting radiopharmaceutical Yttrium-90 (90Y), which is 
characterized by a tissue penetration of 3 to 11 mm. Currently, this agent is indicated primarily for 
knee joints and not for joints with a narrow joint space and a thin soft tissue envelope, such as the 
ankle [14]. 
In this case series, we present our study of five young athletes suffering from PVNS of the ankle 
joint who were treated with synovectomy followed by adjuvant intraarticular RSO with the 
radiopharmaceutical erbium-169 (169Er). 
2. Materials and Methods 
2.1. Patients 
Five young amateur athletes suffering from diffuse PVNS of the ankle joint underwent 
arthroscopic (four patients) or open (one patient) synovectomy between 01/2015 and 01/2017. There 
were three female and two male patients, aged from 20 to 36 years (mean age: 28.2 years). All the 
patients had at least one preoperative contrast-enhanced MRI. In all cases, the diagnosis was 
confirmed by histopathology. The present study was performed in accordance with the ethical 
standards laid down in the 1964 Declaration of Helsinki and all subsequent revisions. All persons 
gave their informed consent prior to their inclusion in the study. 
2.2. y ovecto y 
 art r sc ic e ri e e t f t e s i  as erf r e  er t r i et it  t e se f 
a  a teri r r steri r a le art r sc  r a c i ati  f t e a e ( i re 1). 
 
Figure 1. Arthroscopic image of pigmented villonodular synovitis (PVNS) of the ankle joint ((A,B) 
anterior arthroscopy; (C) posterior ankle arthroscopy) showing the villonodular tissue originating 
from the synovium. 
In the case of a combined anterior and posterior arthroscopy, the operation was performed in 
two stages. In another case, the procedure was combined with a mini open approach, with an 
extension of the arthroscopic portal approach. Finally, in one case, the anterior tibial tendon was also 
involved and an anterior tendon tendoscopy was performed, followed by open debridement. The 
choice of the arthroscopic approach depended on the location of the affected synovium, as shown by 
the imaging studies. All arthroscopies were performed with a regular 3.5 mm 30° angle arthroscope 
and debridement was performed with a combination of 3.5 and 4.0 mm shavers. In cases where the 
synovium extended to the medial and lateral ankle gutters, a 2.7 or 2.9 mm shaver was also utilized. 
Depending on the duration of the procedure and the type of anaesthesia, the patients were treated 
either as a day case or with a one-night hospitalization. A regular postoperative protocol with two 
weeks protected weight-bearing on crutches was implemented in all cases. 
Figure 1. Arthroscopic image of pigmented villonodular synovitis (PVNS) of the ankle joint
((A,B) anterior arthroscopy; (C) posterior ankle arthroscopy) showing the villonodular tissue originating
from the synovium.
In the case of a combined anterior and posterior arthroscopy, the operation was performed in two
stages. In another case, the procedure was combined with a mini open approach, with an extension of
the arthroscopic portal approach. Finally, in one case, the anterior tibial tendon was also involved
and an anterior tendon tendoscopy was performed, followed by open debridement. The choice
of the arthroscopic approach depended on the location of the affected synovium, as shown by the
imaging studies. All arthroscopies were performed with a regular 3.5 mm 30◦ angle arthroscope
and debridement was performed with a combination of 3.5 and 4.0 mm shavers. In cases where the
synovium extended to the medial and lateral ankle gutters, a 2.7 or 2.9 mm shaver was also utilized.
Depending on the duration of the procedure and the type of anaesthesia, the patients were treated
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either as a day case or with a one-night hospitalization. A regular postoperative protocol with two
weeks protected weight-bearing on crutches was implemented in all cases.
2.3. Radiosynoviorthesis (RSO)
All patients had a postsurgical, pre-RSO, three-phase bone scintigraphy, performed not earlier than
two months after synovectomy, which confirmed an increased technetium-99m-methyl diphosphonate
(99mTc-MDP) uptake in the blood pool phase (Figure 2).
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After a local lidocaine injection for analgesia, excess joint fluid—if present—was drained, and
74 MBq of 169Er in a volume of less than 1 mL was injected intraarticularly into the ankle joint, followed
by the administration of 20 mg of triamcinolone acetonide. Immediately after 169Er application, static
imaging of the ankle joint with single-photon emission computed tomography/computed tomography
(SPECT/CT) was performed to demonstrate the distribution of the radiopharmaceutical in the joint
and exclude potential extraarticular leakage (Figure 4). The patients were instructed to avoid excessive
physical activity for the following two days.
J. Clin. Med. 2020, 9, x FOR PEER REVIEW 4 of 8 
 
 
         fl     
 Bq of 169Er in a volume of less than 1 mL was injected intraarticularly into the ankle joint, 
followe  by the administrati n of 20 mg of triamcinolone ace onide. Immediately after 169Er 
applicati n, static imaging of the a kle joint with single-photon e ission computed 
tomography/com uted tomography (SPECT/CT) was performed to demonstrate the distribution of 
the radiopharmaceutical in the joint and excl de potential extraarticular leakage (Figur  4). Th  
atients were instructed to avoid excessive physical activity for the following two days. 
 
Figure 4. Imaging of the ankle joint performed immediately after intraarticular application of 169Er. 
Fused transaxial single-photon emission computed tomography/computed tomography (SPECT/CT) 
(A) and coronal SPECT/CT (B) of the ankle joint excluded potential extraarticular leakage of 169Er. Due 
to the very low intensity γ-rays of 169Er, imaging was performed with co-administration of 185 MBq 
of 99mTc in order to render SPECT/CT imaging feasible. 
2.4. Follow-up 
Joint functional status and pain were assessed by the Foot Function Index (FFI) and a visual 
analog scale (VAS). In particular, FFI is a self-administered index consisting of 23 self-reported items 
divided into 3 subcategories on the basis of patient values: pain, disability, and activity limitation. 
The patients had to describe their foot by scoring each question on a scale from 0 (no pain or difficulty) 
to 10 (worst pain imaginable or so difficult it requires help). Finally, scores ranged from 0 to 100, with 
higher scores indicating worse pain [15,16]. FFI assessment was performed before RSO and on June 
2019 at a median follow up of 47 months (range 36–54 months). 
The VAS score is a unidimensional measure of pain intensity, consisting of a straight line with 
the endpoints defining extreme limits such as ‘no pain at all’ and ‘pain as bad as it could be’ [17]. The 
VAS consists of ten steps: 1—lack of any impairment to 10—total disability. Assessment was 
performed just before (less than twelve days) and two, six and twelve months after RSO, as well as 
at a median follow-up of 470 months (range 3629–5447 months) for all patients. 
3. Results 
The characteristics of the studied patients, as well as the data on the applied treatment, are 
presented in Table 1. A static scintigraphy of the ankle joint with 99mTc (photopeak of 140 keV, 20% 
energy window) immediately after 169Er application confirmed the intraarticular administration of 
the radiopharmaceutical in the joint and excluded extraarticular leakage in all patients (Figure 4). 
  
i r . I i f t e le j i t erf r e i e i tel fter i tr rtic l r lic ti f 169Er.
F se tra saxial si gle- oto e issio co te to ogra y/co te to ogra y (S / )
( ) and coronal SPE T/ T ( ) of the ankle joint excluded potential extraarticular leakage of 169Er. ue
to the very lo intensity γ-rays of 169Er, imaging was performed with co-administration of 185 MBq of
99mTc in order to render SPECT/CT imaging feasible.
2.4. Follow-Up
Joint functional status and pain were assessed by the Foot Function Index (FFI) and a visual
analog scale (VAS). In particular, FFI is a self-administered index consisting of 23 self-reported items
divided into 3 subcategories on the basis of patient values: pain, disability, and activity limitation.
The patients had to describe their foot by scoring each question on a scale from 0 (no pain or difficulty)
to 10 (worst pain imaginable or so difficult it requires help). Finally, scores ranged from 0 to 100, with
higher scores indicating worse pain [15,16]. FFI assessment was performed before RSO and on June
2019 at a median follow up of 47 months (range 36–54 months).
The VAS score is a unidimensional measure of pain intensity, consisting of a straight line with the
endpoints defining extreme limits such as ‘no pain at all’ and ‘pain as bad as it could be’ [17]. The VAS
consists of ten steps: 1—lack of any impairment to 10—total disability. Assessment was performed
just before (less than twelve days) and two, six and twelve months after RSO, as well as at a median
follow-up of 47 months (range 36–54 months) for all patients.
3. Results
The characteristics of the studied patients, as well as the data on the applied treatment, are presented
in Table 1. A static scintigraphy of the ankle joint with 99mTc (photopeak of 140 keV, 20% energy
window) immediately after 169Er application confirmed the intraarticular administration of the
radiopharmaceutical in the joint and excluded extraarticular leakage in all patients (Figure 4).
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Table 1. Characteristics of the studied patients.
Patient No Gender Age Sport Time betweenSynovectomy and RSO Side-Effects
Duration of
Follow-Up (Months)
1 F 20 rhythmic gymnastics 3 months None 44
2 F 25 track and field 3 months None 47
3 M 36 volleyball 5 months None 54
4 F 28 track and field 4 months None 36
5 M 32 football (soccer) 3 months Pain, edema(3 weeks) 50
Radiosynoviorthesis (RSO).
Successive assessment by means of FFI and VAS revealed a marked relief of the pain that
limited daily activities as a percentage of the pretherapeutic joint discomfort. In particular, the FFI
decreased from a median 77% (range 71.0%–84.5%) before treatment to a median of 0.5% (range
0%–6%), as assessed after communication with all patients at a median follow up of 47 months (range
36–54 months) (Table 2).
Table 2. FFI before and after treatment of the studied patients.
Patient No FFI Pre-RSO FFI on January 2020 (Median Follow-Up: 44 Months)
1 84.5% 0.5%
2 73.0% 0.5%
3 77.0% 0%
4 71% 0.5%
5 84.5% 6%
Foot function index (FFI); Radiosynoviorthesis (RSO).
Moreover, the median pre-treatment VAS score was 4 (range 3–7) and decreased after two months
to 1 (range 0–2), after six months to 1 (range 0–1), and after twelve months to 0 (range 0–1). Further, at a
median of 47 months after therapy (range 36–54 months) the median VAS score was further reduced
to 0 (range 0–1) (Table 3). Apart from the long duration of pain relief, all patients reported a further
improvement in their daily activities.
Table 3. VAS score before and after treatment of the studied patients.
Patient No VAS ScorePre-RSO
VAS Score at
2 Months
VAS Score at
6 Months
VAS Score at
12 Months
VAS Score on January 2020
(Median Follow-Up: 44 Months)
1 5 1 1 0 0
2 4 3 1 1 1
3 3 1 0 0 0
4 4 1 0 1 0
5 7 6 2 1 1
Visual analogue scale (VAS); Radiosynoviorthesis (RSO).
Throughout the follow-up period, no major complications regarding either therapeutic intervention
(synovectomy, RSO) were recorded. Only one patient reported pain and edema three weeks after RSO,
which subsided after a week of oral non-steroid anti-inflammatory drugs (NSAIDs).
4. Discussion
RSO has been used for more than 60 years in the treatment of a range of refractory painful
synovitis [18]. The modality is based on the local application of β-emitting isotopes with a therapeutic
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range of only a few millimetres in the affected joint and their subsequent phagocytosis by macrophages
and other inflammatory cells in the articular cavity. The resulting local irradiation of the joint leads to
necrosis of the superficial synovial layers, delaying joint destruction [19]. The therapy is minimally
invasive and well-tolerated with practically no side effects, if well-performed. The main indications
of RSO are rheumatoid arthritis, undifferentiated arthritis characterized by synovitis, ankylosing
spondylitis, psoriatic arthritis, hemophilic arthritis, PVNS, and osteoarthritis, with synovitis as its
primary manifestation [14,20].
PVNS is treated by surgical excision. However, simple resection of the lesion is associated with
local recurrence rates as high as 50% [13]. RSO has been successfully applied in combination with
surgical synovectomy for the treatment of PVNS mainly in the knee with the radiopharmaceutical
90Y [12,21–23]. Nevertheless, no information exists on the application of the β-emitter 169Er in the
ankle joint. The reasons for the usage of 169Er lie in the post-surgical, adjuvant setting of the treatment.
All patients had already undergone synovectomy, thus a large—but not whole—proportion of the
hypertrophic synovium had been surgically removed. Since the main objective of adjuvant RSO was to
complete the resection of the affected tissues, which were no longer markedly hyperthrophic, we chose
to use a radiopharmaceutical with a maximum tissue penetration of up to 1 mm like 169Er and not
the recommended isotope 168Re, which emitts β-particles that have ranges of up to 4.5 mm in tissue.
Another reason for the application of 169Er in this patient cohort is that, during the operation (either
arthroscopic or open debridement), the integrity of the joint capsule is inevitably compromised. In the
postoperative period where RSO is applied, this is only partially repaired with interrupted sutures.
Especially in the case of ankle arthroscopy, only the skin is repaired, with sutures leaving the joint
capsule to heal by itself. This does not provide a true sealant to microleakage. In the case of posterior
involvement in particular, additional facts need to be considered. Firstly, the posterior joint capsule is
located deep to the retrocalcaneal fat pad, with a broad and rather loose attachment to the distal tibia.
This interferes with its healing process, as the effect of tamponade from the postoperative bandages is
minimized. Secondly, the Achilles tendon is unique in that it lacks a true synovial sheath. It is covered
only by a thin layer of paratenon, which makes it more vulnerable to toxicity due to leakage of the
RSO agent. The above reasons reinforce the choice of 169Er citrate, as it offers a good balance between
efficacy and the minimum possible penetration.
The findings of this small case series support the use of 169Er RSO as an effective adjuvant to
the surgical excision of PVNS in the ankle. All five patients responded to the combined treatment
satisfactorily, with significant pain reduction and return to daily activities early after administration of
a single dose of 169Er. Patient follow-up showed an essential reduction in pain intensity as early as
two months after treatment and, more importantly, a lasting effect of the treatment regarding pain
alleviation and ability to perform daily activities, as estimated at a median of 47 months after RSO.
This result is of great importance given the young age (20–36 years) and the strenuous, everyday
activity—as athletes—of the herein treated cohort.
Reports on RSO in the ankle joint with PVNS are scarce [12,13]. Shabat et al. treated three patients
with diffuse PVNS of the ankle joint with debulking surgery, followed by intraarticular injection of
555–925 MBq of the high-energy β-emitter 90Y 6–8 weeks after the last surgery. The reported results
were very satisfying regarding both safety and efficacy [12]. However, six years later, the same group
reported on the treatment of seven patients with PVNS of the ankle with subtotal synovectomy followed
by RSO with 90Y. In that paper, the authors reported extensive complications following intraarticular
injection of the radiopharmaceutical, with all patients suffering from pain associated with redness and
swelling of the involved ankle. More importantly, two patients developed full-thickness skin necrosis
around the injection site, necessitating free muscle flap transfer, while a third patient developed a
draining sinus associated with chronic severe pain [13]. These RSO-related soft tissue complications
were not observed in our study. This discrepancy in toxicity of the two applied treatments can
mainly be attributed to the different physical characteristics of the agents and the technique used: the
β-particles emitted by 90Y have a longer penetration in tissue than 169Er, leading to the irradiation
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of neighboring tissues, mostly the skin, thus causing radiation-induced erythema or skin necrosis.
In fact, this penetration length is the main reason that 90Y is nowadays indicated for large joints, like
the knee, and not for medium-sized joints. Moreover, the doses applied in that study were much
larger in comparison to the ones administered in our study (555 MBq vs. 74 MBq), which could also
contribute to the unacceptable toxicity of the 90Y-RSO. Finally, following the injection of the isotope,
we also administered corticosteroids into the ankle joint in order to reduce inflammation, which was
not reported in the study by Bickels et al.
There are certain limitations in this study. Firstly, it is a relatively small case series. However,
PVNS of the ankle is a very rare disorder, rendering the design of prospective large cohort studies
extremely difficult. To our knowledge, this is the first published report of intraarticular RSO with the
radiopharmaceutical 169Er in PVNS of the ankle following surgical synovectomy. Secondly, although
all patients followed the same protocol regarding the timing and the dose of the RSO, there are certain
variations in the operative management, as dictated by the different manifestations of the disease
itself, leading to the use of an anterior or posterior ankle arthroscopy or a combination of the above.
Nevertheless, all patients responded more than satisfyingly to treatment without variations.
5. Conclusions
Adjuvant intraarticular RSO with 169Er following arthroscopic or open excision is effective and
safe in the treatment of PVNS of the ankle. Long-term follow-up is required to confirm the very
encouraging results presented herein.
Author Contributions: I.I. and C.S. conceived original idea and led the overall study; I.I. and C.S. wrote manuscript;
I.I. performed the RSOs; P.S. performed the synovectomies; I.I. and C.S. performed research and analyzed data;
P.S., D.K. and E.G. provided writing and project administration. All authors have read and agreed to the published
version of the manuscript.
Funding: This research received no external funding.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Granowitz, S.P.; D’Antonio, J.; Mankin, H.L. The pathogenesis and long-term end results of pigmented
villonodular synovitis. Clin. Orthop. Relat. Res. 1976, 114, 335–351.
2. Dorwart, R.H.; Genant, H.K.; Johnston, W.H.; Morris, J.M. Pigmented villonodular synovitis of synovial
joints: Clinical, pathologic, and radiologic features. AJR Am. J. Roentgenol. 1984, 143, 877–885. [CrossRef]
[PubMed]
3. Sharma, H.; Jane, M.J.; Reid, R. Pigmented villonodular synovitis of the foot and ankle: Forty years of
experience from the Scottish bone tumor registry. J. Foot Ankle Surg. 2006, 45, 329–336. [CrossRef] [PubMed]
4. Rochwerger, A.; Groulier, P.; Curvale, G.; Launay, F. Pigmented villonodular synovitis of the foot and ankle:
A report of eight cases. Foot Ankle Int. 1999, 20, 587–590. [CrossRef] [PubMed]
5. Korim, M.T.; Clarke, D.R.; Allen, P.E.; Richards, C.J.; Ashford, R.U. Clinical and oncological outcomes after
surgical excision of pigmented villonodular synovitis at the foot and ankle. Foot Ankle Surg. 2014, 20, 130–134.
[CrossRef]
6. Lee, M.; Mahroof, S.; Pringle, J.; Short, S.C.; Briggs, T.W.; Cannon, S.R. Diffuse pigmented villonodular
synovitis of the foot and ankle treated with surgery and radiotherapy. Int. Orthop. 2005, 29, 403–405.
[CrossRef] [PubMed]
7. Tyler, W.K.; Vidal, A.F.; Williams, R.J.; Healey, J.H. Pigmented villonodular synovitis. J. Am. Acad. Orthop. Surg.
2006, 14, 376–385. [CrossRef]
8. Van der Heijden, L.; Gibbons, C.L.; Dijkstra, P.D.; Kroep, J.R.; van Rijswijk, C.S.; Nout, R.A.; Bradley, K.M.;
Athanasou, N.A.; Hogendoorn, P.C.; van de Sande, M.A. The management of diffuse-type giant cell tumour
(pigmented villonodular synovitis) and giant cell tumour of tendon sheath (nodular tenosynovitis). J. Bone
Joint Surg. Br. 2012, 94, 882–888. [CrossRef]
J. Clin. Med. 2020, 9, 597 8 of 8
9. O’Sullivan, B.; Cummings, B.; Catton, C.; Bell, R.; Davis, A.; Fornasier, V.; Goldberg, R. Outcome following
radiation treatment for high-risk pigmented villonodular synovitis. Int. J. Radiat Oncol. Biol. Phys. 1995, 32,
777–786. [CrossRef]
10. Brien, E.W.; Sacoman, D.M.; Mirra, J.M. Pigmented villonodular synovitis of the foot and ankle. Foot Ankle Int.
2008, 29, 527–533. [CrossRef]
11. Schnirring-Judge, M.; Lin, B. Pigmented villonodular synovitis of the ankle-radiation therapy as a primary
treatment to reduce recurrence: A case report with 8-year follow-up. J. Foot Ankle Surg. 2011, 50, 108–116.
[CrossRef]
12. Shabat, S.; Kollender, Y.; Merimsky, O.; Isakov, J.; Flusser, G.; Nyska, M.; Meller, I. The use of surgery and
yttrium 90 in the management of extensive and diffuse pigmented villonodular synovitis of large joints.
Rheumatology (Oxford) 2002, 41, 1113–1118. [CrossRef]
13. Bickels, J.; Isaakov, J.; Kollender, Y.; Meller, I. Unacceptable complications following intra-articular injection
of yttrium 90 in the ankle joint for diffuse pigmented villonodular synovitis. J. Bone Joint Surg Am. 2008, 90,
326–328. [CrossRef]
14. Knut, L. Radiosynoviorthesis in the Therapeutic Management of Arthritis. World J. Nucl. Med. 2015, 14,
10–15. [CrossRef]
15. Budiman-Mak, E.; Conrad, K.J.; Roach, K.E. The Foot Function Index: A measure of foot pain and disability.
J. Clin. Epidemiol. 1991, 44, 561–570. [CrossRef]
16. Kulig, K.; Reischl, S.F.; Pomrantz, A.B.; Burnfield, J.M.; Mais-Requejo, S.; Thordarson, D.B.; Smith, R.W.
Nonsurgical Management of Posterior Tibial Tendon Dysfunction with Orthoses and Resistive Exercise: A
Randomized Controlled Trial. Phys. Ther. 2009, 89, 26–37. [CrossRef]
17. Haefeli, M.; Elfering, A. Pain assessment. Eur. Spine J. 2006, 15 (Suppl. 1), S17–S24. [CrossRef]
18. Fellinger, K.; Schmid, J. Die lokale Behandlung der rheumatischen Erkrankungen. Wien. Z Inn Med. 1952, 33,
351–363.
19. Van der Zant, F.M.; Boer, R.O.; Moolenburgh, J.D.; Jahangier, Z.N.; Bijlsma, J.W.; Jacobs, J.W. Radiation
synovectomy with (90)Yttrium, (186)Rhenium and (169)Erbium: A systematic literature review with
meta-analyses. Clin. Exp. Rheumatol. 2009, 27, 130–139.
20. Schneider, P.; Farahati, J.; Reiners, C. Radiosynovectomy in rheumatology, orthopedics, and hemophilia.
J. Nucl Med. 2005, 46 (Suppl. 1), 48S–54S.
21. Chen, D.Y.; Lan, J.L.; Chou, S.J. Treatment of pigmented villonodular synovitis with yttrium-90: Changes in
immunologic features, Tc-99m uptake measurements, and MR imaging of one case. Clin. Rheumatol 1992, 11,
280–285. [CrossRef]
22. Kat, S.; Kutz, R.; Elbracht, T.; Weseloh, G.; Kuwert, T. Radiosynoviorthesis in pigmented villonodular
synovitis. Nuklearmedizin 2000, 39, 209–213. [PubMed]
23. Koca, G.; Ozsoy, H.; Atilgan, H.I.; Ozyurt, S.; Demirel, K.; Yiğit, H.; Korkmaz, M.; Baskin, A.; Sakaogullari, A.;
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